FDA Opens Guidance for Comment On Drug-Induced Liver Injury

摘要

Drugmakers and the public can suggest revisions to or comment on a draft guidance for industry issued in July 2009 on drug-induced liver injury (DILI), the FDA says.rnThe comment period coincides with a scientific and regulatory conference the FDA held last month with the American Association for the Study of Liver Diseases and PhRMA to evaluate recommendations received since last July.